Boehringer Ingelheim's novel antibody shows potential to transform treatment of rare form of psoriasis
The New England Journal of Medicine (NEJM) today published new data from a Phase I clinical trial showing BI 655130, a first-in-class investigational treatment, significantly improved symptoms of generalised pustular psoriasis (GPP), a rare form of psoriasis.1
BI 655130 is a monoclonal antibody that blocks the action of the interleukin-36 receptor (IL-36R), a signalling pathway within the immune system that may play a role in many inflammatory diseases.
The newly published clinical data, which were also presented at the recent American Academy of Dermatology (AAD) annual meeting in Washington D.C.,2 indicate that BI 655130 rapidly improved symptoms in seven patients with GPP, who were experiencing acute moderate or severe disease flares.1 Five of seven patients in the 20-week, Phase I clinical trial achieved clear or almost clear skin within the first week, following a single dose of treatment, and all patients achieved this outcome after four weeks.1 The average improvement in patients’ skin symptoms was close to 80 per cent at week four and was maintained until the end of the study (week 20).1
“The tailored targeting of the IL-36 pathway is one of the most exciting new areas in dermatology research, and progress in this mechanism has been eagerly anticipated by the scientific community,” commented the trial’s principal investigator, Professor Hervé Bachelez, Hôpital Saint-Louis, Paris, France. “This trial provides long-awaited clinical data that demonstrates the positive effect of blocking IL-36 action as a potential, novel treatment approach. The rapid improvement seen in patients from just a single dose of BI 655130 show strong potential for the future treatment of GPP.”
The rare skin disease, GPP, is a chronic condition that is distinct from the more common condition, plaque psoriasis.3 It has a considerable impact on people’s quality of life. The skin becomes red and erupts into numerous blisters of non-infectious pus (pustules), covering wide areas of the body.4,5,6 People who develop GPP may experience an abrupt onset of fever, chills and painful skin lesions.4,5,6 GPP may be associated with life-threatening organ failure and infectious complications, and, therefore, should be considered a medical emergency.7 Available treatment options for GPP are extremely limited and lack profound and persistent efficacy. Therefore, there is a strong need for new treatment options for GPP with rapid, strong and persistent efficacy.8
“BI 655130 is a novel antibody discovered by Boehringer Ingelheim and is being investigated for the treatment of multiple inflammatory diseases in the hope of transforming the care currently available for these patients,” said Dr Jan Poth, Therapeutic Area Head, CNS and Immunology at Boehringer Ingelheim.
“We are one of the first companies to focus on targeting IL-36 in dermatology, a reflection of our long-term commitment to researching and developing transformative medicines for patients where there is still high unmet need. Due to its potential, we are moving to the next phase of clinical trials, involving larger numbers of patients with GPP. Trials of BI 655130 are also underway in other immune related conditions, such as palmo-plantar pustulosis, ulcerative colitis, Crohn’s disease and atopic dermatitis,” continued Poth.
The Phase I trial is the first of its kind to include patients who were experiencing an acute, moderate-to-severe flare of GPP.1
Each of the seven patients received a single intravenous dose of BI 655130 and was monitored for 20 weeks.1 The severity of GPP was assessed using the Generalized Pustular Psoriasis Physician Global Assessment score and the Generalized Pustular Psoriasis Area and Severity Index score.
- At the end of week one, clear or almost clear skin was achieved in five of seven patients, and in all study participants by week four.1
- At the end of week two, a 73.2 per cent average improvement in skin symptoms was observed in all study participants.1
- Overall, BI 655130 was well tolerated with no drug-related severe or serious adverse events or safety signals.1
BI 655130 is the second compound developed by Boehringer Ingelheim’s immunology division; the first, risankizumab, an IL-23 blocker is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading future development and commercialisation of risankizumab globally.
About Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company, therefore, concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company, therefore, aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
*BI 655130 is an investigational compound. Its safety and efficacy have not been established.
Please click on the following link for ‘References’: http://www.boehringer-ingelheim.com/press-release/nejm-il-36-phase-1-gpp-data
Media + PR
Phone: +49 6132 – 77 8271
Fax: +49 6132 – 77 6601
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Earth Networks and RIMES Announce Technical Collaboration to Benefit Member Government Weather Services27.3.2019 02:00:00 EET | Tiedote
Earth Networks, a global provider of weather intelligence, announced today it has partnered with the Regional Integrated Multi-Hazard Early Warning System for Africa and Asia (RIMES). The partnership will enable a multi-year collaboration program to enhance RIMES’ member state National Hydro-Meteorological Services (NMHS) capacity for early warning of severe weather. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Together, the two organizations are working to improve access to reliable weather information and early warning capabilities in Africa and Asia. By contributing on-the-ground insights from its weather and lightning networks, Earth Networks is providing critical hyperlocal data to RIMES to help regional NMHS close weather observation gaps in real-time and support more accurate forecasting. These technology enhancements will result in quicker warnings to the public before and during severe weather events. Earth Networks has years of experience
Huawei Rewrites the Rules of Photography with Groundbreaking HUAWEI P30 Series26.3.2019 19:04:00 EET | Tiedote
During an exclusive launch event today at the Paris Convention Center, Huawei Consumer Business Group (BG) unveiled the HUAWEI P30 and HUAWEI P30 Pro. The HUAWEI P30 Series builds on the HUAWEI P Series DNA in design and photography and is the company’s most advanced series of smartphone cameras. These devices feature the innovative HUAWEI SuperSpectrum Sensor, an optical SuperZoom Lens, a new HUAWEI Time of Flight (ToF) Camera, and enhanced optical and AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro capture incredible photos and videos in every scenario. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005752/en/ HUAWEI P30 Series (Photo: Business Wire) Richard Yu, CEO of Huawei Consumer BG, said, “the HUAWEI P30 Series is a fundamental breakthrough after decades of digital camera technology development; it will rewrite the rules and reshape everyone’s percepti
Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism26.3.2019 18:01:00 EET | Tiedote
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential long-term risks of renal and cardiovascular complications that patients treated with conventional therapy may experience. Six-year results from the open-label long-term safety and efficacy RACE study were also announced. Data was presented at the Endocrine Society’s 2019 Annual Meeting (ENDO) from 23–26 March in New Orleans, Louisiana, USA. “Results from the Burden of Illness Global Survey in 13 countries reveal the extent of the impact hypoparathyroidism has on patients and their caregivers throughout their daily lives,” said John Bilezikian M.D., Professor of Medicine at the Columbia University Irving Medical Center, New York, NY, USA. “This offers important insights and enables us to take a more holistic approach in the management of these patients due to a greater understanding of the poten
LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development26.3.2019 17:58:00 EET | Tiedote
Veeva Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader in medical dermatology, selected Veeva Development Cloud applications to help drive end-to-end business processes across product development. The company will utilize the Vault Clinical, Vault RIM, and Vault Quality suites to unify drug development on a single cloud platform. With Veeva Development Cloud, LEO Pharma can bring together applications for clinical, regulatory, and quality for even greater efficiency and compliance throughout the product development lifecycle. “LEO Pharma R&D has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to continuously pioneer dermatology. This requires that we are able to drive science globally, whilst at the same time securing timely delivery on our pipeline,” said Kim Kjøller, executive vice president of global research and development at LEO Pharma. “Veeva Development Cloud gives us a unified platform that can enable us to maximize eff
Keio Plaza Hotel Tokyo Hosts Japanese Sword Culture, Armor Exhibition – “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans”26.3.2019 17:05:00 EET | Tiedote
Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host a special exhibition entitled “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans” displaying beautiful Japanese swords and armor from April 25 (Thursday) to June 27 (Thursday), 2019 in the 3rd floor lobby of our Hotel. This exhibition is part of our series of cultural programs designed to introduce various aspects of Japanese culture to our guests visiting the Hotel from over 100 different countries around the world. Various precious and old swords and armor made during the Heian Period (794-1185) and other periods of Japanese history will be displayed, along with “tsuba” (Sword handle guards separating the handle from the blade) and other ornate sword fittings. On May 14, two masters of sword-drawing from Ryushin Shouchi School will give a live performance in the Main lobby from 5:00 p.m. This press release features multimedia. View the full release
Andersen Global Enters Qatar26.3.2019 16:30:00 EET | Tiedote
Andersen Global today announced a collaborating agreement in Qatar with Al-Khalifa Law, a leading Doha-based law firm. The collaboration is Andersen Global’s first in Qatar and is part of the organization’s continued growth in the Middle East. Al-Khalifa Law was founded 20 years ago and established itself as a premier firm in the region. The team at Al-Khalifa Law has diversified, deep experience providing services in a wide variety of business sectors, such as commercial contracts, taxation, employment, real estate and retail, intellectual property, dispute resolution and litigation and arbitration. “A collaboration with Andersen Global, which brings with it a culture of stewardship, transparency, and providing best-in-class services, was an obvious decision for us,” said Hamzeh Abdelhady, Office Managing Director of Al-Khalifa Law. “We will be able to continue providing quality services in the market and bring a premier, seamless association of experts throughout the world directly t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme